78. Hypopituitarism
462 clinical trials,   346 drugs   (DrugBank: 45 drugs),   41 drug target genes,   80 drug target pathways

Searched query = "Hypopituitarism", "Anterior pituitary hypothyroidism", "Syndrome of abnormal secretion of gonadotropin", "Hyposecretion of gonadotropins", "Adrenocorticotropic hormone deficiency", "ACTH deficiency", "Thyroid-stimulating hormone deficiency", "TSH deficiency", "Growth hormone deficiency", "GH deficiency", "GHD", "CGHD", "AGHD", "Prolactin deficiency", "PRL deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
17 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-005587-82-GR
(EUCTR)
28/11/200728/06/2007A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of PHA-794428 in Adult Growth Hormone Deficient patients - N/AA Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of PHA-794428 in Adult Growth Hormone Deficient patients - N/A Adult Growth Hormone Deficiency
MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Pfizer LtdNULLNot RecruitingFemale: yes
Male: yes
170Czech Republic;United Kingdom;Netherlands;Denmark;Italy;Greece;Poland;Sweden
2EUCTR2005-005587-82-PL
(EUCTR)
07/07/200731/05/2007A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/AA Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/A Adult Growth Hormone Deficiency
MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Pfizer LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
170Czech Republic;United Kingdom;Netherlands;Denmark;Italy;Greece;Poland;Sweden
3EUCTR2005-005587-82-CZ
(EUCTR)
15/02/200725/10/2006A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/AA Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/A Adult Growth Hormone Deficiency
MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Pfizer LimitedNULLNot RecruitingFemale: yes
Male: yes
170United Kingdom;Czech Republic;Netherlands;Denmark;Italy;Greece;Poland;Sweden
4EUCTR2005-005587-82-NL
(EUCTR)
08/08/200612/05/2006A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/AA Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/A Adult Growth Hormone Deficiency
MedDRA version: 8.1;Level: LLT;Classification code 10056438
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
PfizerPfizerNot RecruitingFemale: yes
Male: yes
136Czech Republic;United Kingdom;Netherlands;Denmark;Italy;Greece;Poland;Sweden
5EUCTR2005-005587-82-IT
(EUCTR)
02/08/200623/06/2006A DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS - NDA DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS - ND Adult growth hormone deficiency AGHD .
MedDRA version: 6.1;Level: PT;Classification code 10056438
Product Code: PHA-794,428
Product Code: PHA-794,428
PFIZERNULLNot RecruitingFemale: yes
Male: yes
136Czech Republic;United Kingdom;Netherlands;Denmark;Italy;Greece;Poland;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2005-005593-79-BE
(EUCTR)
31/07/200611/05/2006A Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency - N/AA Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency - N/A Paediatric Growth Hormone Deficiency
MedDRA version: 8.1;Level: LLT;Classification code 10056438
Product Name: N/A
Product Code: PHA-794428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Product Name: N/A
Product Code: PHA-794428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Pfizer N.V./S.A.NULLNot RecruitingFemale: yes
Male: yes
32Spain;Belgium;Germany;United Kingdom
7EUCTR2005-005587-82-BE
(EUCTR)
03/07/200622/03/2006A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/AA Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/A Adult Growth Hormone Deficiency
MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Pfizer NV/SANULLNot RecruitingFemale: yes
Male: yes
170Czech Republic;Greece;Poland;Belgium;Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden
8NCT00308464
(ClinicalTrials.gov)
July 200627/3/2006A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone DeficiencyA Double Blind Parallel Group Randomised Multiple Dose Study To Evaluate The Pharmacodynamic Response And Safety Of PHA-794428 In Adult Growth Hormone Deficient PatientsGrowth Hormone DeficiencyDrug: PHA-794428PfizerNULLTerminated18 Years65 YearsBoth136Phase 2Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Slovakia;Spain;Sweden;United Kingdom
9EUCTR2005-005587-82-DE
(EUCTR)
21/06/200606/03/2006A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/AA Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/A Adult Growth Hormone Deficiency
MedDRA version: 8.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Pfizer Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
136Czech Republic;Greece;Poland;Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden
10EUCTR2005-005587-82-SE
(EUCTR)
12/06/200602/03/2006A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/AA Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/A Adult Growth Hormone Deficiency
MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Pfizer AB;Pfizer LtdNot RecruitingFemale: yes
Male: yes
170Czech Republic;United Kingdom;Netherlands;Denmark;Italy;Greece;Poland;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2005-005593-79-DE
(EUCTR)
09/06/200603/04/2006A Double blind, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency - N/AA Double blind, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency - N/A Paediatric Growth Hormone Deficiency
MedDRA version: 8.1;Level: LLT;Classification code 10056438
Product Name: N/A
Product Code: PHA-794428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Product Name: N/A
Product Code: PHA-794428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Pfizer Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
32United Kingdom;Germany;Spain
12EUCTR2005-005593-79-GB
(EUCTR)
02/06/200621/03/2006A Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency - N/AA Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency - N/A Paediatric Growth Hormone Deficiency
MedDRA version: 8.1;Level: LLT;Classification code 10056438
Product Name: N/A
Product Code: PHA-794428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Product Name: N/A
Product Code: PHA-794428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Pfizer LimitedNULLNot RecruitingFemale: yes
Male: yes
32Germany;United Kingdom;Spain
13EUCTR2005-005593-79-ES
(EUCTR)
31/05/200604/04/2006A Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiencyA Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency Paediatric Growth Hormone Deficiency
MedDRA version: 8.1;Level: LLT;Classification code 10056438
Product Code: PHA-794428
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Product Code: PHA-794428
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Pfizer SANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
32Germany;United Kingdom;Spain
14EUCTR2005-005587-82-GB
(EUCTR)
17/05/200620/04/2006A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/AA Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/A Adult Growth Hormone Deficiency
MedDRA version: 8.1;Level: LLT;Classification code 10056438
Product Code: PHA-794,428
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Product Code: PHA-794,428
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Pfizer LimitedNULLNot RecruitingFemale: yes
Male: yes
136Czech Republic;United Kingdom;Netherlands;Denmark;Italy;Greece;Poland;Sweden
15EUCTR2005-005587-82-DK
(EUCTR)
26/04/200615/03/2006A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/AA Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/A Adult Growth Hormone Deficiency
MedDRA version: 8.1;Level: LLT;Classification code 10056438
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Product Name: N/A
Product Code: PHA-794,428
INN or Proposed INN: N/A
Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH
Pfizer LimitedNULLNot RecruitingFemale: yes
Male: yes
136Czech Republic;United Kingdom;Netherlands;Denmark;Italy;Greece;Poland;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00314938
(ClinicalTrials.gov)
April 200613/4/2006A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone DeficiencyA Double Blind, Single Dose Study To Explore The Safety, Pharmacokinetics And Pharmacodynamics Of PHA-794428 In Pediatric Patients With Growth Hormone DeficiencyGrowth Hormone DeficiencyDrug: PHA-794428PfizerNULLTerminated6 Years12 YearsBoth32Phase 2Belgium;France;Germany;Israel;United Kingdom;Spain
17EUCTR2005-001658-25-BE
(EUCTR)
16/06/200505/07/2005An open label, two period crossover study to explore the safety, pharmacokinetics and pharmacodynamics of PHA-794428 after single subcutaneous injections in adult male patients with growth hormone deficiency.An open label, two period crossover study to explore the safety, pharmacokinetics and pharmacodynamics of PHA-794428 after single subcutaneous injections in adult male patients with growth hormone deficiency. AGHD Adult Growth Hormone DeficiencyProduct Code: PHA-794428
Product Code: PHA-794428
Pfizer Global Research and DevelopmentNULLNot RecruitingFemale: no
Male: yes
8Belgium